Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials
Lamivudine population pharmacokinetics were investigated by using nonlinear mixed-effect modelling (NONMEM) analysis of data from 394 human immunodeficiency virus (HIV)-infected patients treated with lamivudine (150 to 300 mg every 12 h) in two large, phase III clinical efficacy-safety trials, NUCA3...
Kaydedildi:
| Yayımlandı: | Antimicrob Agents Chemother |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Microbiology (ASM)
1999
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89609/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10582904/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.12.3025 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|